Erratum: Deficiency of NRH: Quinone Oxidoreductase 2 Increases Susceptibility to 7,12-Dimethylbenz(a)anthracene and Benzo(a)pyrene-Induced Skin Carcinogenesis (Cancer Research (2004) 64 (5925-5928) DOI: 10.1158/0008-5472.CAN-04-0763);Deficiency of NRH:Quinone oxidoreductase 2 increases susceptibility to 7,12-dimethylbenz(a)anthracene and benzo(a)pyrene-induced skin carcinogenesis

Cancer Research

Volumn 64, Issue 17, 2004, Pages 5925-5928

  Iskander, Karim ^a   Paquet, Marilene ^a   Brayton, Cory ^a   Jaiswal, Anil K ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZO[A]PYRENE; CARCINOGEN; DIMETHYLBENZ[A]ANTHRACENE; PHORBOL 13 ACETATE 12 MYRISTATE; PROTEIN BAX; PROTEIN P21; PROTEIN P53; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE);

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER SUSCEPTIBILITY; CHEMICAL CARCINOGENESIS; CONTROLLED STUDY; ENZYME DEFICIENCY; HISTOPATHOLOGY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SKIN CANCER; SKIN CARCINOGENESIS; SKIN TUMOR; TUMOR SUPPRESSOR GENE;

EID: 4344569485     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-22-0499     Document Type: Erratum

References (20)

1. Collins JF, Brown JP, Alexeeff GV, Salmon AG. Potency equivalency factors for some polycyclic aromatic hydrocarbons and polycyclic aromatic hydrocarbon derivatives. Regul Toxicol Pharmacol 1988;28:45-54.
2. Gelboin HV. Benzo(a)pyrene metabolism, activation and carcinogenesis: role and regulation of mixed-function oxidases and related enzymes. Physiol Rev 1980;60: 1107-66.
3. Chesis PL, Levin DE, Smith MT, Emster L, Ames BN. Mutagenicity of quinones: pathways of metabolic activation and detoxification. Proc Natl Acad Sci USA 1984;81:1696-700.
4. Radjendirane V, Joseph P, Jaiswal AK. Gene expression of DT-diaphorase (NQO1) in cancer cells. In: Forman HJ, Cadenas E, editors. Oxidative stress and signal transduction. New York: Chapman & Hall, 1997; p. 441-75.
5. Talalay P. Mechanisms of induction of enzymes that protect against chemical carcinogenesis. Adv Enzyme Regul 1989;28:149-59.
6. Riley RJ, Workman P. DT-diaphorase and cancer chemotherapy. Biochem Pharmacol 1992;43:1657-69.
7. Wu K, Knox R, Sun XZ, et al. Catalytic properties of NAD(P)H:quinone oxidoreductase2 (NQO2), a dihydronicotinamide riboside dependent oxidoreductase. Arch Biochem Biophys 1997;345:221-8.
8. Zhao Q, Yang XL, Holtzclaw WD, Talalay P. Unexpected genetic and structural relationships of a long-forgotten flavoenzyme to NAD(P)H:quinone reductase (DT-diaphorase). Proc Natl Acad Sci USA 1997;94:1669-74.
9. Knox RJ, Jenkins TC, Hobbs SM, Chen S, Melton RG, Burke PJ. Bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) by human NAD(P)H: quinone oxidoreductase 2: a novel co-substrate-mediated antitumor prodrug therapy. Cancer Res 2000;60:4179-86.
10. Foster CE, Bianchet MA, Talalay P, Zhao Q, Amzel LM. Crystal structure of human quinone reductase type 2, a metalloflavoprotein. Biochemistry 1999;38:9881-6.
11. Jaiswal AK, Bell DW, Radjendirane V, Testa JR. Localization of human NQO1 gene to chromosome 16q22 and NQO2-6p25 and associated polymorphism. Pharmacogenetics 1999;9:413-8.
12. Jaiswal AK, Burnett P, Adesnik M, McBride OW. Nucleotide and deduced amino acid sequence of a human cDNA (NQO2) corresponding to a second member of the NAD(P)H:quinone oxidoreductase gene family. Extensive polymorphism at the NQO2 gene locus on chromosome 6. Biochemistry 1990;29:1899-906.
13. Radjendirane V, Joseph P, Lee H, et al. Disruption of the DT diaphorase (NQO1) gene in mice leads to increased menadione toxicity. J Biol Chem 1998;273: 7382-9.
14. Long DJ, Iskander K, Gaikwad A, et al. Disruption of dihydronicotinamide riboside:quinone oxidoreductase 2 (NQO2) leads to myeloid hyperplasia of bone marrow and decreased sensitivity to menadione toxicity. J Biol Chem 2002;277: 46131-9.
15. Gaikwad A, Long DJ II, Stringer JL, Jaiswal AK. In vivo role of NAD(P)H:quinone oxidoreductase 1 (NQO1) in the regulation of intracellular redox state and accumulation of abdominal adipose tissue. J Biol Chem 2001;276:22559-64.
16. Long DJ II, Gaikwad A, Multani A, et al. Disruption of the NAD(P)H:quinone oxidoreductase 1 (NQO1) gene in mice causes myelogenous hyperplasia. Cancer Res 2002;62:3030-6.
17. Long DJ II, Waikel RL, Wang X, Perlaky L, Roop DR, Jaiswal AK. NAD(P)H: quinone oxidoreductase 1 deficiency increases susceptibility to benzo(a)pyrene-induced mouse skin carcinogenesis. Cancer Res 2000;60:5913-5.
18. Long DJ II, Waikel RL, Wang XJ, Roop DR, Jaiswal AK. NAD(P)H:quinone oxidoreductase 1 deficiency and increased susceptibility to 7,12-dimethylbenz[a] -anthracene-induced carcinogenesis in mouse skin. J Natl Cancer Inst (Bethesda) 2001;93:1166-70.
19. Anwar A, Dehn D, Siegel D, et al. Interaction of human NAD(P)H:quinone oxidoreductase 1 (NQO1) with the tumor suppressor protein p53 in cells and cell-free systems. J Biol Chem 2003;278:10368-73.
20. Asher G, Lotem J, Tsvetkov P, Reiss V, Sachs L, Shaul Y. p53 hot-spot mutants are resistant to ubiquitin-independent degradation by increased binding to NAD(P)H: quinone oxidoreductase. Proc Natl Acad Sci USA 2003;100:15065-70.